Evelo Biosciences
General Information | |
Business: |
Evelo Biosciences is discovering and developing potential therapies designed to act on the gut-body network. The action of our therapies is based on our growing understanding of the central role of the gut in controlling immune and biological activity throughout the body. The gut-body network represents the connections of the gut to all organs and tissues, which enables the gut to exert a significant level of control over the body’s immune and biological systems.
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 59 |
Founded: | 2014 |
Contact Information | |
Address | 620 Memorial Drive, Suite 200, Cambridge, MA 02139, US |
Phone Number | (617) 577-0300 |
Web Address | http://www.evelobio.com |
View Prospectus: | Evelo Biosciences |
Financial Information | |
Market Cap | $509.9mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-34.1 mil (last 12 months) |
IPO Profile | |
Symbol | EVLO |
Exchange | NASDAQ |
Shares (millions): | 5.3 |
Price range | $16.00 - $16.00 |
Est. $ Volume | $85.0 mil |
Manager / Joint Managers | Morgan Stanley/ Cowen/ BMO Capital Markets |
CO-Managers | JMP Securities |
Expected To Trade: | 5/9/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |